With a registered capital of 1.2 billion RMB, we are the vaccine division flagship of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. - a prominent subsidiary of China's renowned Yangshengtang Group. As Fujian Province's sole privately-held biotechnology enterprise dedicated to vaccine R&D and production, we represent a unique combination of scientific innovation and manufacturing excellence in China's vaccine landscape.

For nearly two decades since its founding, Innovax has been at the forefront of vaccine innovation, dedicated to developing high-quality, affordable vaccines for global disease prevention. Through our unique collaboration with the National Institute of Diagnostics and Vaccine Development of Infectious Diseases (NIDVD) - a joint initiative between Yangshengtang Group and Xiamen University - we have pioneered a sustainable industry-academia-research model. Our achievements include establishing the world's first recombinant Escherichia coli virus-like particle (VLP) vaccine platform, which has yielded groundbreaking vaccines like Hecolin® (the world's first recombinant Hepatitis E vaccine) and Cecolin® (China's first domestically developed HPV vaccine and the fourth globally approved).